Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 526

1.
2.
3.

Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.

Jermendy G; Hungarian RECAP Group, Erdesz D, Nagy L, Yin D, Phatak H, Karve S, Engel S, Balkrishnan R.

Health Qual Life Outcomes. 2008 Oct 31;6:88. doi: 10.1186/1477-7525-6-88.

4.

Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.

Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:8-15. doi: 10.1111/j.1463-1326.2008.00881.x.

PMID:
18435669
5.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
6.

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.

Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR.

Diabetes Care. 2005 May;28(5):995-1000.

PMID:
15855556
8.

Oral antidiabetic medication adherence and glycemic control in managed care.

Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS.

Am J Manag Care. 2008 Feb;14(2):71-5.

9.
10.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
12.

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.

Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:25-32. doi: 10.1111/j.1463-1326.2008.00882.x.

PMID:
18435671
13.

2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.

Seufert J, Urquhart R.

Diabetes Res Clin Pract. 2008 Mar;79(3):453-60. Epub 2007 Dec 26.

PMID:
18160120
15.
17.

Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.

Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H.

Curr Med Res Opin. 2004;20(2):215-23.

PMID:
15006017
18.

Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?

Kirk JK, Pearce KA, Michielutte R, Summerson JH.

J Fam Pract. 1999 Nov;48(11):879-82.

PMID:
10907625
20.

Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.

Thayer S, Arondekar B, Harley C, Darkow TE.

Ann Pharmacother. 2010 May;44(5):791-9. doi: 10.1345/aph.1M426. Epub 2010 Apr 6.

PMID:
20371759
Items per page

Supplemental Content

Write to the Help Desk